Today, researchers at the University of Michigan, MoreBetter (Releaf App), LEVEL, and Overcome announced they are recruiting California residents to participate in a 12-week study focusing on the efficacy of different cannabinoid capsules and tablets for managing chronic pain related to Fibromyalgia, Rheumatoid Arthritis, Osteoarthritis and overall quality of life.
This study aims to address the significant gaps in cannabinoid research related to efficacy for specific types of chronic pain, different product formulations, and dosing. Normalizing the product type to tablets and capsules, this is one of the first studies to look at efficacy trends related to dosing combined with unique product formulations.
There are upwards of 40 million individuals living with these conditions and even more battling chronic pain. This study is a step in the direction of helping patients and practitioners have a better understanding of how to use cannabinoid medicine as a natural and effective therapy.
Eligible study participants living in California can participate in this study from the comfort and safety of their home by using their smartphone to questionnaires. The study’s delivery partner, FLOWER CO (a licensed California delivery answer standardized pain and quality of life company), will deliver study products to participants.
Enrolled participants will receive a 12-week supply of study product from LEVEL and Overcome. Participants who complete the study may receive up to $500 in Amazon Gift Cards. Individuals interested in enrolling can do so at releaf.at/umpain.
“Pain is one of the most common conditions people use medical cannabis to treat, and the U.S. National Academies of Sciences, Engineering, and Medicine has concluded that cannabis is effective in pain relief,” says Daniel Kruger, PhD, the study’s Principal Investigator. “This conclusion is just the beginning, we need more research to know how to optimize pain relief with cannabis. This cross-sector partnership is critical for overcoming regulatory barriers to cannabis research and enhancing trust by including independent academic researchers.”
“Data shows cannabinoids are effective at helping individuals manage or reduce chronic pain, however, there is little data on what specific formulation, administration form, and dose is most efficacious,” says Tyler Dautrich, COO of MoreBetter Ltd., the company behind Releaf App. “This study is important because by normalizing the administration form we can more accurately monitor dosing regimens leading to better insights on condition-specific efficacy as it relates to product formulation.”
“Cannabinoids have a myriad of therapeutic properties, and we’re just starting to define their positive impact on human health,” said LEVEL Founder and CEO Chris Emerson, PhD. “At LEVEL, we’re dedicated to conducting research, pushing the scientific boundaries, and driving consumer education about cannabinoids, which facilitates our unique approach to developing innovative cannabis products. Leveraging real-world clinical evidence on the potential health benefits of cannabis will shape the future of the industry, and LEVEL is excited to participate in this important work.”
“We have received great anecdotal reviews as to our Active Relief formulation to date but having a formal study on the product compared to other product formulas is essential for furthering the future of cannabinoid medicine, not just for Overcome but the industry at large,” explained Annie Rouse, Founder of Overcome. “Given our formulary research, we are confident that our product will help the patients in the study overcome pain and inflammation and we look forward to the feedback provided.”
"FLOWER CO. has always been a natural fit for the medical user trying to afford their medicine, so we're excited to give back to the community by enabling this study so that science can catch up to how impactful cannabis can be," said Ted Lichtenberger, CEO of FLOWER CO.
About MoreBetter
MoreBetter (dba Releaf App) is a data insights Software-as-a-Service provider and contract research organization supported by patent-pending technology that collects real-world evidence-based outcomes from cannabis & hemp consumers to benefit businesses, medical professionals, researchers, government organizations, and affiliated stakeholders in the cannabis supply chain. MoreBetter uses information collected in Releaf App to provide data- backed insights on seed-to-outcome trends that inform industry best practices and improve the consumer experience.
About the University of Michigan and the Principal Investigator
The University of Michigan (UM) is ranked #1 in research volume among U.S. research universities, with over $1.5 billion in research expenditures in 2021. UM is consistently ranked among the top for both U.S. public universities and university reputations globally. Daniel Kruger, PhD, has published over a dozen peer-reviewed scientific articles on the medicinal use of cannabis, including in the top journals in the field.
About LEVEL
LEVEL is a science-driven cannabis company at the forefront of cannabinoid research and innovation that is passionate about helping to guide humans with the information and products they need to make informed decisions and take action. We launched LEVEL with one goal in mind: to create unique, targeted, effects-based cannabis products by formulating cannabinoids in ratios inaccessible from the plant alone.
About OP Innovates
Overcome LLC, a subsidiary of OP Innovates, is a natural supplement brand that formulates for optimized absorption, targeted recovery and responsive results. Overcome uses patented, organic bioavailability technology, powered by Naturia+, and science-based formulations to empower you to achieve your desired lifestyle. Initially started with the mission of supporting our Founders journey to overcome Lyme Disease, Overcome donates 1% of sales to Lyme Disease research and education. At Overcome we believe the first step is to say you can.
This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News at the speed of influence™. Reference URL for this press release is here.
